Effient
Product Images NDC 54868-6238

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Effient (NDC 54868-6238). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Physicians Total Care, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Of 10 mg Package Label (6238)

Label for Effient 10 mg tablets distributed by Physicians Total Care, Inc. It includes lot number, expiration date, and indicates manufacture by Eli Lilly and Company, Indianapolis, IN. The package contains 30 tablets and shows the NDC 54868-6238-0 along with a barcode.*

FDA Label Image

Chemical Structure (Effient Tablets 01)

Chemical structure of the active ingredient in Effient, showing its molecular framework including a thiophene ring, cyclopropyl group, fluorophenyl group, and hydrochloride salt.*

FDA Label Image

Figure 1 (Effient Tablets 07)

A line graph comparing the percentage of non-CABG-related TIMI major or minor bleeding events over time between Effient and Clopidogrel. The x-axis represents days from randomization up to 450 days, and the y-axis shows the percentage of bleeding events. Effient's curve is higher than Clopidogrel's, indicating a higher percentage over time. Number of patients at risk is shown below the x-axis for both medications at various time points.*

FDA Label Image

Figure 2 (Effient Tablets 08)

A line graph showing the inhibition of platelet aggregation (%) over time (hours) with mean ± SD at 20 μM ADP concentration. The graph depicts inhibition reaching above 70% within 1 hour, maintaining a high level up to 24 hours.*

FDA Label Image

Figure 3 (Effient Tablets 09)

A line graph comparing cardiovascular death, nonfatal MI, or nonfatal stroke percentages over 450 days from randomization between Clopidogrel and Effient in UA/NSTEMI patients. Clopidogrel shows a higher event rate than Effient, with p-values of 0.002 and 0.017 in the main and inset graphs respectively.*

FDA Label Image

Figure 3 (Effient Tablets 10)

A line graph comparing cardiovascular death, nonfatal myocardial infarction (MI), or nonfatal stroke percentages over days from randomization between two treatments: Effient and Clopidogrel in STEMI patients. The graph shows cumulative event rates with Effient having lower rates than Clopidogrel, including p-values indicating statistical significance.*

FDA Label Image

Figure 4 (Effient Tablets 11)

A forest plot titled 'Baseline Characteristics' comparing hazard ratios for Effient versus Clopidogrel across various patient subgroups based on age, gender, body weight, region, diabetes, metabolic syndrome, previous cardiac events, and other factors. The plot visually represents the effect of each subgroup with confidence intervals on a hazard ratio scale from 0.2 to 2.0.*

FDA Label Image

Figure 5 (Effient Tablets 12)

A forest plot chart comparing baseline characteristics and percent events between Effient and Clopidogrel. It lists subgroups such as age, gender, body weight, region, diabetes status, metabolic syndrome, prior medical conditions, time from symptom onset, stent type, and GP IIb/IIIa inhibitor use. The chart plots hazard ratios with confidence intervals to show comparative event rates between the two drugs across these variables.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.